Form 4: Summit Therapeutics Director Kenneth Clark Granted Stock Options

Director Kenneth Clark of Summit Therapeutics Inc. was granted stock options on January 2, 2025, as part of his director retainer.

Summary

• Kenneth Clark, a director at Summit Therapeutics Inc., was granted two stock option awards on January 2, 2025.
• The first option is for 35,000 shares at an exercise price of $18.35.
• The second option is for 16,991 shares at an exercise price of $18.35.
• Both options vest in four quarterly installments, contingent on Mr. Clark remaining a non-salaried director.
• The second option was granted in lieu of $155,900 in retainer fees.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning director and shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service from the director.
• The use of options in lieu of cash retainer fees can conserve company cash.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the director leaves the board before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The options will vest quarterly based on the director's continued service.

Industry Context

Granting stock options to directors is a common practice in the biotechnology industry to align their interests with shareholders and incentivize performance.

Comparison to Industry Standards

• Stock option grants to non-executive directors are a standard practice in the biotech industry, often used as part of a compensation package.
• The vesting schedule of quarterly installments is also typical, ensuring continued service from the director.
• The exercise price of $18.35 is a key factor, as it determines the potential value of the options for the director.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their director compensation packages, though the specific terms and amounts vary.

Stakeholder Impact

• Shareholders may view the stock option grants positively as they align director interests with company performance.
• The director benefits from the potential upside of the company's stock price.

Next Steps

• The options will vest quarterly based on the director's continued service.
• The director may exercise the options at any time after vesting.

Key Dates

Keywords

stock options, director compensation, Summit Therapeutics, equity, vesting, retainer fees, Kenneth Clark